RFA-DA-23-006: Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R01 - Clinical Trial Required)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on August 11, 2023.
From the official notice on Grants.gov, last changed February 25, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsRequired
- Funded byNIDA
- Median yearly award$661,225
- Typical project length5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under RFA-DA-23-006 were run by National Institute on Drug Abuse (NIDA, 3 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DA-23-006 in the NIH Guide.
Key dates
| Posted | February 25, 2022 |
|---|---|
| Deadline | August 11, 2023 |
| Archived by Grants.gov | September 16, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
There has been a substantial increase in the number of syringe service programs (SSPs) in the US and the range of these settings has become broader, with many now located in health department or FQHCs, in addition to the more traditional CBO and AIDS Service Organization settings. There is a need to provide models for bringing sustainable integrated HIV prevention and care into SSP settings. Newer SSPs often are in settings that have limited expertise for other substance use services and may be limited in terms of HIV care. More established SSPs may provide HIV testing, but often do not directly provide other HIV prevention and care services and rely on referrals with limited follow-up. SSPs provide opportunities for regular contact with PWID and their network members (including non-injectors) which may enable greater engagement and re-engagement across the HIV continua of prevention and treatment. Newer SSPs often are in rural areas with limited capacity to provide a range of HIV services and the COVID pandemic has required restructuring of services and has led to some closures. CDC is developing infrastructure to better monitor SSP programs, survey clients, and develop technical assistance models for SSPs. A program of implementation-focused research to improve HIV prevention and care would complement this effort, as well as SAMHSAs support of these settings.
Funded under RFA-DA-23-006 so far
NIH funded 3 projects under RFA-DA-23-006 in fiscal 2023 to 2026, at 2 institutions. The median yearly award was $661,225.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Comprehensive HIV service provision for people who use drugs in rural areas | Johns Hopkins University | 2026 | $1.2 million |
| Project ACCESS: Advancing Access to HIV/HCV Testing Through Transformation in Syringe Services Programs: A Cluster Randomized Trial | University of Miami School of Medicine | 2026 | $653,862 |
| In pursuit of a one-stop shop: a hybrid type 1 effectiveness-implementation trial of comprehensive tele-health concierge for people who inject drugs | University of Miami School of Medicine | 2026 | $605,728 |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DA-23-006 still open?
No. It closed on August 11, 2023.
Who can apply for Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R01 - Clinical Trial Required)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R01 - Clinical Trial Required)?
Closed August 11, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-DA-23-006?
NIH RePORTER lists 3 projects funded under RFA-DA-23-006 in fiscal 2023 to 2026, at 2 institutions. The most were at University of Miami School of Medicine, Johns Hopkins University.
Who has won Drug Use and Addiction Research Programs grants before?
The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)